GreenLight Biosciences Profit Margin

GreenLight Biosciences (GRNA) currently reports a profit margin of -1549.12% as of March 2023. That compares with -12584.61% in the prior-year period — up 87.7% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore GreenLight Biosciences's profit margin history and peer comparisons.

GreenLight Biosciences's profit margin increased from -12584.61% to -1549.12% — a 87.7% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GreenLight Biosciences's profit margin of -1549.12% is lower than the its sector sector average of 13.23%. That is roughly 11812.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but GreenLight Biosciences's current -1549.12% should be judged against industry norms (sector average: 13.23%) and against GRNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1549.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for GreenLight Biosciences, and consider following GRNA for alerts when major investors trade the stock.